PUBLISHER: The Business Research Company | PRODUCT CODE: 1945466
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945466
The rapid test based on Lateral Flow Immunoassay (LFIA) is a straightforward technology-driven diagnostic device employed for detecting the presence of specific targets, such as pathogens or biomarkers, in samples obtained from the human body. These samples encompass various bodily fluids such as urine, saliva, blood, and sweat.
The primary techniques include the competitive assay, sandwich assay, and multiplex detection assay. The competitive assay specifically determines the presence of targets, such as pathogens or biomarkers, within the collected samples. Its applications span infectious diseases, pregnancy and fertility assessments, toxicology, and others, making it applicable in diverse settings such as hospitals, clinics, diagnostic laboratories, home care, and more.
Tariffs are influencing the LFIA based rapid test market by increasing costs of imported antibodies, membranes, nanoparticles, reader components, and packaging materials. Healthcare systems and diagnostic manufacturers in North America and Europe are most affected due to reliance on imported raw materials, while Asia-Pacific faces cost pressure on large-scale test production. These tariffs are increasing unit costs and affecting affordability. At the same time, they are driving domestic manufacturing, local sourcing of assay components, and innovation in cost-efficient rapid test formats.
The lateral flow immunoassay (lfia) based rapid test market research report is one of a series of new reports from The Business Research Company that provides lateral flow immunoassay (lfia) based rapid test market statistics, including lateral flow immunoassay (lfia) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (lfia) based rapid test market share, detailed lateral flow immunoassay (lfia) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (lfia) based rapid test industry. This lateral flow immunoassay (lfia) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The lateral flow immunoassay (lfia) based rapid test market size has grown steadily in recent years. It will grow from $7.17 billion in 2025 to $7.31 billion in 2026 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to expansion of rapid infectious disease screening, increasing adoption of pregnancy and fertility tests, growth of point-of-care diagnostics, availability of low-cost rapid tests, rising public health screening initiatives.
The lateral flow immunoassay (lfia) based rapid test market size is expected to see steady growth in the next few years. It will grow to $8.67 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing investments in decentralized diagnostics, expansion of self-testing applications, growing demand for rapid cardiac and toxicology tests, rising integration with digital health platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing demand for rapid immunoassay-based testing, rising adoption of home-use lfia kits, growing use of multiplex detection assays, expansion of infectious disease testing applications, enhanced focus on user-friendly test design.
The rising prevalence of chronic diseases is expected to drive growth in the lateral flow immunoassay (LFIA) based rapid test market. Chronic diseases, also referred to as non-communicable diseases (NCDs), are long-term health conditions that persist over extended periods, often throughout a person's lifetime. LFIA-based rapid tests facilitate early detection, point-of-care testing, rapid results, ongoing monitoring, and reduced healthcare costs associated with chronic disease management. These tests are valued for providing quick and accessible results, allowing healthcare professionals and patients to make timely decisions regarding treatment and lifestyle adjustments. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported that 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. As a result, the growing prevalence of chronic diseases is supporting the expansion of the LFIA-based rapid test market.
Companies in the market are focusing on advanced diagnostic technologies to improve efficiency and patient care. Integrated Health Solutions, for instance, connect healthcare services, technologies, and data to enhance workflow and collaboration across healthcare platforms. In June 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, launched analytical units for its Cobas Pro integrated solutions. The system can process up to 1,000 samples per hour using its sample supply unit and perform up to 900 tests per hour for ion-selective electrode (ISE) analysis and 1,000 tests per hour on the Cobas C 503 unit for clinical chemistry, streamlining laboratory operations and improving patient care.
In August 2023, Danaher Corporation, a US-based medical products company, acquired Abcam plc for $5.7 billion. This acquisition aligns with Danaher's strategy to expand its life sciences business and support clients in addressing major healthcare challenges. Abcam plc, a UK-based biotechnology company, specializes in the manufacture of LFIA-based rapid tests, and the acquisition is expected to enhance value for shareholders while delivering improved outcomes for employees and clients.
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., PerkinElmer Inc., Hologic Inc., LTEK Co. Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience(R) Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd, Qiagen N.V., Merck KGaA, 3a Diagnostics, Roche Holding AG, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, CTK Biotech
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the lateral flow immunoassay (lfia) based rapid test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
Lateral Flow Immunoassay (LFIA) based rapid test market consists of sales of conjugate pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses lateral flow immunoassay (lfia) based rapid test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for lateral flow immunoassay (lfia) based rapid test ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lateral flow immunoassay (lfia) based rapid test market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.